Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.
2.

Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.

Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, Graells ML, Gutiérrez F.

Clin Ther. 2007 Jul;29(7):1448-55.

PMID:
17825696
3.

Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy.

Bucher HC, Rickenbach M, Young J, Glass TR, Vallet Y, Bernasconi E, Cavassini M, Fux C, Schiffer V, Vernazza P, Weber R, Battegay M; Swiss HIV Cohort Study.

Antivir Ther. 2010;15(1):31-40. doi: 10.3851/IMP1475.

PMID:
20167989
4.

[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].

Panel de expertos de GESIDA y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2011 Mar;29(3):209.e1-103. doi: 10.1016/j.eimc.2010.12.004. Spanish.

PMID:
21388714
5.

[Coronary heart disease risk factors in Croatia and worldwide: results of the Interheart study].

Carević V, Rumboldt M, Rumboldt Z; Interheart Investigators.

Acta Med Croatica. 2007 Jun;61(3):299-306. Croatian.

PMID:
17629106
6.

Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy.

Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, Frank I, Maartens G, Nachega JB.

PLoS Med. 2008 May 20;5(5):e109. doi: 10.1371/journal.pmed.0050109.

7.

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group.

AIDS. 2003 May 23;17(8):1179-93.

PMID:
12819520
8.

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

Vidal C, García F, Gatell JM, Leal M, Clotet B, Pumarola T, Miró JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):55-60.

PMID:
9732070
9.

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.

Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD; EuroSIDA study group.

HIV Med. 2007 Mar;8(2):96-104.

10.

Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):379-84.

PMID:
14640384
11.

Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M; Swiss HIV Cohort Study.

Clin Infect Dis. 2005 Aug 1;41(3):361-72. Epub 2005 Jun 24.

PMID:
16007534
12.
13.

Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.

Mocroft A, Ledergerber B, Zilmer K, Kirk O, Hirschel B, Viard JP, Reiss P, Francioli P, Lazzarin A, Machala L, Phillips AN, Lundgren JD; EuroSIDA study group and the Swiss HIV Cohort Study.

AIDS. 2007 Sep 12;21(14):1867-75.

PMID:
17721094
14.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
15.

Adherence to the Mediterranean diet is associated with a lower risk of body-shape changes in Croatian patients treated with combination antiretroviral therapy.

Turcinov D, Stanley C, Rutherford GW, Novotny TE, Begovac J.

Eur J Epidemiol. 2009;24(5):267-74. doi: 10.1007/s10654-009-9330-2. Epub 2009 Mar 26.

16.

Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.

Madeddu G, Porqueddu EM, Cambosu F, Saba F, Fois AG, Pirina P, Mura MS.

Infection. 2008 Jun;36(3):231-6. doi: 10.1007/s15010-007-7162-0. Epub 2008 May 10.

PMID:
18463787
17.

Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.

Castagna A, Galli L, Torti C, D'Arminio Monforte A, Mussini C, Antinori A, Cozzi-Lepri A, Ladisa N, De Luca A, Seminari E, Gianotti N, Lazzarin A.

Antivir Ther. 2010;15(2):165-75. doi: 10.3851/IMP1513.

PMID:
20386071
18.

Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions.

Moreira Guimarães MM, Bartolomeu Greco D, Ingles Garces AH, de Oliveira AR Jr, Bastos Fóscolo R, de Campos Machado LJ.

Int J Clin Pract. 2010 May;64(6):739-45. doi: 10.1111/j.1742-1241.2009.02248.x.

PMID:
20518949
19.
20.

Supplemental Content

Support Center